Abstract
Purpose
This study aimed to determine the potential of positron emission tomography/computed tomography (PET/CT) in replacing routine bone-marrow biopsies (BMB) in newly diagnosed extranodal natural killer/T-cell lymphoma (ENKTCL).
Methods
Newly diagnosed patients underwent PET/CT imaging and routine BMB to assess bone/bone marrow involvement (BMI). Clinical stage and treatment plan were determined, and survival was compared.
Results
In a total of 101 patients, 78 were diagnosed as stage I/II and 23 as stage III/IV without using the BMB results. No BMB-positive patients were identified in stages I/II, and therefore, the BMB results did not alter the stage and treatment choice in any patients. The sensitivity and specificity of focal skeletal PET/CT lesion(s) in assessing BMI was 100% and 92.8%, respectively, taking routine BMB as the reference standard. The overall survival (OS) and progression-free survival (PFS) of BMB-positive patients was significantly inferior (P = 0.0011 and 0.0465, respectively, in advanced-stage patients; both P < 0.0001 in all patients), and this was corroborated by the PET/CT findings (P = 0.0006 and 0.0116, respectively, in advanced-stage patients; both P < 0.0001 in all patients).
Conclusions
Based on the results, PET/CT demonstrated satisfactory predictive performance in terms of staging and prognosis in ENKTCL. BMB did not influence staging and treatment in newly diagnosed ENKTCL, and routine non-targeted BMB is not obligatory for early stage patients undergoing PET/CT. Targeted BMB is recommended to confirm BMI in advanced-stage patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams HJA, Kwee TC (2015) Critical views on the prognostic potential and interpretation of bone marrow F-18-FDG PET in diffuse large B-cell lymphoma. J Nucl Med 56:163–164. https://doi.org/10.2967/jnumed.114.148577
Adams HJA, Kwee TC, de Keizer B, Fijnheer R, de Klerk JMH, Littooij AS, Nievelstein RAJ (2014) Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 25:921–927. https://doi.org/10.1093/annonc/mdt533
Adams HJA, de Klerk JMH, Fijnheer R, Dubois SV, Nievelstein RAJ, Kwee TC (2015) Paget’s disease of the bone mimicking lymphomatous bone marrow involvement at FDG-PET. Am J Hematol 90:269–270. https://doi.org/10.1002/ajh.23921
Au W-Y et al (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931–3937. https://doi.org/10.1182/blood-2008-10-185256
Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy—a review of UK data for 2004. Haematol Hematol J 91:1293–1294
Berthet L et al (2013) In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with F-18-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54:1244–1250. https://doi.org/10.2967/jnumed.112.114710
Brunetti GA et al (2011) Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol 90:1233–1235. https://doi.org/10.1007/s00277-011-1166-7
Cencini E et al (2014) Evaluation of the prognostic role of tissue associated macrophages (TAM) in Hodgkin lymphoma and correlation with early FDG-PET assessment. Haematologica 99:397–398
Cerci JJ et al (2014) Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med 55:1591–1597. https://doi.org/10.2967/jnumed.113.134486
Cerci JJ, Fanti S, Redondo F, Gyoerke T, Carr R (2015) Critical views on the prognostic potential and interpretation of bone marrow F-18-FDG PET in diffuse large B-cell lymphoma reply. J Nucl Med 56:164. https://doi.org/10.2967/jnumed.114.150086
Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 38:1469–1476. https://doi.org/10.1007/s00259-011-1815-z
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059. https://doi.org/10.1200/jco.2013.54.8800
Deng TX, Zhang C, Zhang X, Wu S, Xu YQ, Liu SS, Chen XH (2014) Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal-type natural killer/T cell lymphoma: a meta-analysis. Plos One 9:e106577. https://doi.org/10.1371/journal.pone.0106577
Dreyling M et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677–2684. https://doi.org/10.1182/blood-2004-10-3883
El-Galaly TC et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30:4508–4514. https://doi.org/10.1200/jco.2012.42.4036
Fowler N, Asatiani E, Cheson B (2008) Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. Leuk Lymphoma 49:156–158. https://doi.org/10.1080/10428190701732846
Fujiwara H et al (2011) The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma. Eur J Haematol 87:123–129. https://doi.org/10.1111/j.1600-0609.2011.01645.x
Harris NL et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849
Heron DE, Andrade RS, Beriwal S, Smith RP (2008) PET-CT in radiation oncology—the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol Cancer Clin Trials 31:352–362. https://doi.org/10.1097/coc.0b013e318162f150
Hopkins E, Devenish G, Evans G, Leopold G, Rees J, Parry-Jones N (2014) Subcutaneous seeding of ‘double hit’ diffuse large B-cell lymphoma from staging bone marrow biopsy. Br J Haematol 166:635. https://doi.org/10.1111/bjh.12979
Hu C (2016) Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type. Nucl Med Commun Nucl Med Commun 37:446–452
Hutchings M et al (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica Hematol J 91:482–489
Jiang M et al (2017) A phase II prospective study of the “Sandwich” protocol, l-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Oncotarget 8:50155–50163. https://doi.org/10.18632/oncotarget.16334
Karantanis D et al (2008) The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 8:94–99. https://doi.org/10.3816/clm.2008.n.010
Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, Carr R (2013) PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122:61–67. https://doi.org/10.1182/blood-2012-12-473389
Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, Kim WS (2015) Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol 94:71–78. https://doi.org/10.1007/s00277-014-2171-4
Kwee TC, de Klerk JMH, Nievelstein RAJ (2011) Imaging of bone marrow involvement in lymphoma: state of the art and future directions. Sci World J 11:391–402. https://doi.org/10.1100/tsw.2011.40
Lee J et al (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612–618. https://doi.org/10.1200/jco.2005.04.1384
Li YX et al (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181–189. https://doi.org/10.1200/jco.2005.03.2573
Li Y-X et al (2012) Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 82:1809–1815
Liang J-H et al (2017) Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by F-18-FDG PET/CT in extra-nodal NK/T-cell lymphoma. Oncotarget 8:1737–1743. https://doi.org/10.18632/oncotarget.13873
Muslimani AA et al (2008) The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol Cancer Clin Trials 31:409–412. https://doi.org/10.1097/coc.0b013e318168d90b
Oshimi K (2007) Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532–544. https://doi.org/10.1111/j.1365-2141.2007.06835.x
Pak K et al (2017) Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. https://doi.org/10.1016/j.amjoto.2017.10.009
Smith SD, Redman M, Dunleavy K (2015) FDG PET-CT in follicular lymphoma: a case-based evidence review Blood 125:1078–1082. https://doi.org/10.1182/blood-2014-11-537522
Storto G et al (2010) Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br J Haematol 151:195–197. https://doi.org/10.1111/j.1365-2141.2010.08335.x
Suh C et al (2008) Prognostic value of tumor F-18-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49:1783–1789. https://doi.org/10.2967/jnumed.108.053355
Wang YQ, Yang Y, Zhuo HY, Zou LQ, Jiang Y, Jiang M (2015) Trial of LVDP regimen (l-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma. Med Oncol. https://doi.org/10.1007/s12032-014-0435-4
Wu H-B, Wang Q-S, Wang M-F, Li H-S, Zhou W-L, Ye X-H, Wang Q-Y (2010) Utility of F-18-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun 31:195–200. https://doi.org/10.1097/mnm.0b013e32833310fa
Yang L, Liu H, Xu X-h, Wang X-f, Huang H-m, Shi W-y, Jiang S-h (2013) Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med Oncol (Northwood, London, England) 30:720. https://doi.org/10.1007/s12032-013-0720-7
Yhim HY et al (2014) Prognostic significance of interim positron emission tomography scan in patients with mature T-cell and NK-cell lymphoma. Haematologica 99:699
Yiqin W et al (2015) The promise of PET/CT-based bone marrow assessment in replacing routine bone marrow biopsy for staging and prognosis of extranodal natural killer/T-cell lymphoma. Ann Oncol 26:86
Zhou X, Lu K, Geng L, Li X, Jiang Y, Wang X (2014) Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma a systematic review and meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000000258
Zhou Z et al (2015) Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT. Ann Hematol 94:963–967. https://doi.org/10.1007/s00277-014-2289-4
Acknowledgements
This study has no specific funding. We are grateful to the patients in this trial and clinical staff from the pathology and nuclear medicine departments of West China Hospital for their assistance.
Author information
Authors and Affiliations
Contributions
YW and MJ performed the research. MJ designed the research study. Other authors analyzed the data; YW and MJ wrote the paper.
Corresponding author
Ethics declarations
Conflict of interest
The authors declared no conflict of interest to this work.
Ethical approval
We abided by ethical standards of the institutional and/or national research committee, the Helsinki Declaration in 1964 and its later amendments or comparable ethical standards in all procedures performed in this study and all human participants involved.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclosures
Parts of the abstract in this study were invited as an oral presentation in ESMO ASIA Congress 2015, while we did not publish the data and enlarged further research for 3 years. The previous material was presented thoroughly transparent (Yiqin et al. 2015).
Rights and permissions
About this article
Cite this article
Wang, Y., Xie, L., Tian, R. et al. PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. J Cancer Res Clin Oncol 145, 2529–2539 (2019). https://doi.org/10.1007/s00432-019-02957-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02957-5